Background. It is well known that dialysis patients with diabetic nephropathy have a poor prognosis, but data concerning the survival of dialysis patients with diabetes plus a non-diabetic primary nephropathy or the survival of patients who develop diabetes after the start of regular dialysis are scarce. Aim and methods. We reviewed the survival of two cohorts of dialysis patients in whom diabetes mellitus was associated with non-diabetic primary nephropathy. In the first cohort (18 patients with a primary diagnosis of APKD) diabetes mellitus preceded hyperazotaemia, whilst the second cohort of 34 patients developed diabetes after the start of regular dialysis. We compared the survival of each group of patients to the survival of a group of dialysis patients with a primary diagnosis of diabetic nephropathy, and to the survival of a control group of non-diabetic dialysis patients. Within each case series, groups were similar according to age, sex, age at start of RRT, and place of treatment. All patients were selected among those alive on treatment at 31 December 1987 and were followed up to 31 December 1991. Results. In both case series the survival of patients with diabetes was similar irrespective of the primary diagnosis (Lee-Desu statistics: first cohort P=0.43; second cohort, P = 0.08). Moreover, the survival of patients either with diabetic nephropathy or with diabetes in association with hon-diabetic primary nephropathy was significantly worse compared to the survival of the non-diabetic patients (Lee-Desu statistics: first case series P = 0.02 and / > <0.01; second case series /><0.05 and / 3 <0.01). Logistic regression showed that survival was negatively associated to diabetes and age but not to sex, duration of diabetes and diagnosis of diabetic nephropathy. Conclusions. Our limited data show that the survival of diabetic patients on regular dialysis is poor, irre-
Introduction
Diabetic nephropathy is the most common cause of uraemia in the US and one of the most common in Canada, Australia, and some European countries [1, 2] . It has even been suggested that Europe may soon face an epidemic level of diabetes-related end-stage renal disease cases [2] .
Apart from its relevance to the ESRD issue as a cause of uraemia, diabetes is a prominent cause of accelerated artherosclerosis and an important risk factor for cardiovascular disease and premature death. Indeed, most if not all papers investigating risk factors in dialysis populations have identified diabetic nephropathy as an independent risk factor for shorter survival [3] [4] [5] [6] and, even for dialysis termination [7] .
In uraemic patients the issue of diabetes has nearly always been raised together with the issue of diabetic nephropathy [3] [4] [5] [6] , whilst few papers have made the point that in these patients, diabetes may coexist with a non-diabetic nephropathy. When diabetes is already known by the time renal failure is diagnosed, it may be difficult to distinguish between diabetic nephropathy or nephropathy plus coexisting diabetes. On the other hand there are situations in which the diagnosis of diabetic nephropathy can be easily ruled out, i.e. when diabetes develops once chronic dialysis treatment is started {de novo diabetes) or after kidney transplantation (post transplantation diabetes).
It could be expected that diabetes influences both the quality of life and the survival of chronic dialysis patients, even if it is not the primary cause of renal failure. Post-transplantation diabetes has raised some interest from clinicians and researchers [8] [9] [10] [11] [12] [13] [14] . However, there is little information available on the impact of diabetes on the survival of patients with non-diabetic primary renal diseases [15] [16] [17] and we are not aware of any report concerning the survival of patients with de novo diabetes in dialysis. In the following pages therefore, we will review two case series of diabetic and non-diabetic patients on RRT, focusing on the issue of the impact of diabetes mellitus on the survival of dialysis patients when this disease is not the direct cause of end-stage renal disease.
Subjects and methods
In 1987 we performed a retrospective analysis on 65 diabetic patients in RRT treated in three Italian renal units [17] . The results showed that there was no difference in the survival between the 42 patients with a primary diagnosis of diabetic nephropathy and the 23 with a non-diabetic primary nephropathy. However, these data were subject to criticism since very few patients have been biopsied. Therefore we decided to confirm and extend these preliminary results by studying two specific subsets of patients amongst all diabetic patients that were treated by RRT in Italy at the end of 1987 [18] .
In 1988 we identified 1605 diabetic patients that were treated by RRT in Italy at the end of 1987 [18] by asking, on one hand, the dialysis units to report about the diabetic patients on RRT together with diabetes' characteristics, and on the other, by obtaining information concerning primary diagnosis and story of RRT treatment from the ANED Registry [18] . For 1576 of the diabetic patients, we were able to identify a non-diabetic control patient similar according to age, sex, age at start of RRT, and unit of treatment. In 234 of the diabetic patients a primary non-diabetic renal disease was reported [18] .
Amongst these 3152 patients alive on treatment at 31 December 1987, we selected the following two case series of patients:
to
Diabetes together with non-diabetic nephropathies
We compared 18 diabetic patients who had a primary diagnosis of adult polycystic kidney disease (APKD) with 1125 18 diabetic patients with a primary diagnosis of diabetic nephropathy and with 18 non-diabetic dialysis patients. These three groups were similar for age, year at start of RRT, sex, first type of dialysis treatment (HD, PD), and age at diagnosis of diabetes (groups 1 and 2) ( Table 1) . None of the patients have ever been transplanted. These patients were followed up to the end of 1991.
Apparent de novo diabetes mellitus in maintenance RRT
In 44/1605 (2.7%) diabetic patients, diabetes was reported to have been diagnosed after the start of RRT. In 7/44 patients the diagnosis of diabetes was made following kidney transplantation, and in one patient before transplantation, whilst the remaining 36 patients were never transplanted. In these 36 patients, diabetes was diagnosed on average 4.2 + 3.0 years after the start of RRT (Figure 1 ). Two patients were on treatment with CAPD when diabetes was diagnosed whilst the other 34 were treated by haemodialysis. After diabetes was diagnosed, 20 patients were treated by insulin and the rest by tablets or by diet alone. We matched by age, sex, year of starting RRT, region of treatment, and negative Data are expressed as mean (SD). "EDTA classification. history for transplantation: 34 of the patients with de novo diabetes with 34 patients with a primary diagnosis of diabetic nephropathy and 34 non diabetic dialysis patients ( Table 2 ). The follow-up of these patients was available to the end of 1991.
Statistical analysis
Data were stored on a microcomputer using the Dbase 3 plus (Ashton Tate, 1986) database and then analysed by using the Statistical Program for the Social Sciences (SPSS inc., Chicago, 1990) . Comparison between groups were performed using the analysis of variance and the chi-square statistics. Comparison between survival curves have been performed using the Lee-Desu statistic. The impact of age, age at start of RRT, sex, diabetes, diabetes as diabetic nephropathy on survival was analysed by logistic regression using the outcome (death, alive) as dichotomous dependent variable.
Results
In both case series, when all patients were pooled together only diabetes and age (/ > <0.01) were independently associated to the survival, whilst sex, year of starting RRT, primary diagnosis of DN, and diabetes duration (diabetic patients only) were not.
Diabetic patients with a primary diagnosis of APKD exhibit a similar survival compared to the patients with a primary diagnosis of diabetic nephropathy. On the other hand, the control group demonstrated better survival compared to both diabetic groups (APKD-(-diabetes vs DN P=0.44; APKD + diabetes vs controls, P<0.01; DN versus controls, />=0.02) (Figure 2 ). At the end of the 4-year observation period, the number of deaths in each group were 11, 9 and 3 respectively. The distribution of the causes of death was not different between the diabetic groups (Table 3) .
In the second cohort, the survival of patients with de novo diabetes was not significantly different to the Percentages are in brackets. Cardiovascular mortality was the main cause of death in diabetic patients irrespective of whether diabetes was the cause of ESRD or not survival of patients with DN (P = 0.08), whilst both these groups had a worse survival compared to the controls {de novo diabetics versus controls, / > <0.01; diabetic nephropathy vs controls, P<0.05) (Figure 3 ). The cumulative survival at 4 years was 35%, 59% and 74% for the de novo diabetes, the diabetic nephropathy patients and the control patients respectively. The review of the causes of death (Table 4) Percentages are in brackets. Cardiovascular mortality was the main cause of death in both diabetic groups.
the proportion of cardiovascular deaths was similar in both diabetic groups.
Discussion
Our data show that diabetes bears a negative impact on patients' survival irrespective of the primary diagnosis. We are aware that our patients were not biopsied. Thus it could not be absolutely excluded that some of the patients with a primary diagnosis of nondiabetic nephropathy actually suffered from diabetic renal disease, and that some patients with a primary diagnosis of DN had a primary non-diabetic nephropathy. However, among 234 patients with a primary non-diabetic renal disease, we selected only 18 with APKD in order to be reasonably sure about the primary diagnosis. To the same extent, in the second cohort it appears very unlikely that the primary renal disease was diabetic nephropathy when diabetes was diagnosed only after the start of chronic dialysis. Even if it could not be excluded that some of the patients in the DN groups had a non-diabetic renal disease, we don't think that few misdiagnoses would alter substantially the message of this paper.
In any case, data already available show similar survival figures for diabetic patients with non-diabetic primary nephropathies. Apart from our preliminary report [17] , Koch et al. have reported similar data both for what survival and causes of death are concerned [15] . More recently Nicolucci et al. have pointed out that the presence of comorbid conditions including diabetes affect the survival in patients with RRT [16] .
It was somewhat amazing to find out such a poor outcome in the patients with de novo diabetes within a 4-year follow-up, and it is difficult to find a satisfactory explanation for this finding. Reports concerning de novo diabetes in dialysis patients are scarce [19] [20] [21] [22] and the survival issue has never been addressed in these patients. However, it has been shown in a matched-pair control study, that within 10 years, posttransplantation diabetes affects both patient and graft survival [13] . We believe that the poor outcome of patients with de novo diabetes might be related to the presence of some factor causing both diabetes and 1127 systemic damage or, alternatively, related to the emergence of an additional risk factor in already compromised patients. It is even possible that in these patients, diabetes is secondary to the medical treatment of some dialysis-related condition [22] . The potential hazards of glucose intolerance in uraemic patients have been discussed previously in detail by DeFronzo and Smith [23] .
It was found to be somewhat strange that survival was not related to the duration of diabetes. However the lack of this particular finding may be explained on the grounds that the duration of diabetes is often apparent and because it could be expected that diabetes bears a different impact on survival in different patients. We ourselves have not found a significant association between duration of diabetes and survival in the overall diabetic patients that were alive on RRT at the end of 1987 and that were followed up to the end of 1991 (unpublished data). Unfortunately in these patients, no detailed information concerning common risk factors (such as smoking, measures of adiposity or hypertension) were available, but we think that a systematic error in the case mix is unlikely.
Conclusions
Diabetes in patients with (end-stage) renal disease is not diabetic nephropathy alone. Probably, around 20% of overall diabetic patients on RRT had non-diabetic renal disease, and around 2-10% of overall diabetic patients on RRT develop the illness after chronic treatment was started [22] .
From our data, it looks as if diabetes has a very strong impact on survival even if it is not the primary cause of uraemia or even if it appears only after dialysis is started. This finding if confirmed would recommend an aggressive approach on cardiovascular risk factors in all diabetic patients with signs of renal impairment irrespective of the primary diagnosis.
In these pages, we have tried to discuss issues that up till now have not received very much attention from the medical literature. We don't feel we are in the position to draw any firm conclusions since available data are somewhat lacking and far from consolidated. We are also aware that presented data coming from our survey are open to criticism since they were in part retrospective, because of the lack of renal biopsies, and because the Italian survey of diabetic dialysis patients was not primarily aimed at addressing the issue of de novo diabetes in dialysis.
However, it is felt that these issues are of interest and we conclude with the hope that this paper may induce other nephrologists with interest in clinical diabetes to review and report their own data concerning diabetes as a co-existing disease or de novo diabetes in RRT. It would also be of interest to study prospectively both the main cardiovascular risk factors and the quality of life of these patients. Finally, we wonder if the major dialysis registries should consider the possibility of adding to the information they already collect, some data concerning the major cardiovascular risk factors, such as diabetes, hypertension and smoking habits.
